Drug resistance associated genetic polymorphisms in Plasmodium falciparum and Plasmodium vivax collected in Honduras, Central America

Malaria Journal

Volumn 10, Issue , 2011, Pages

  Jovel, Irina T ^a,b   Mejía, Rosa E ^c   Banegas, Engels ^c   Piedade, Rita ^d,e   Alger, Jackeline ^b   Fontecha, Gustavo ^b   Ferreira, Pedro E ^d   Veiga, Maria I ^a   Enamorado, Irma G ^b   Bjorkman, Anders ^a   Ursing, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL AUTONOMOUS UNIVERSITY OF HONDURAS   (Honduras)

^c Laboratorio Nacional de Referencia de Tuberculosis   (Honduras)

^d KAROLINSKA INSTITUTE   (Sweden)

^e UNIVERSITY OF ALGARVE   (Portugal)

Author keywords

Chloroquine; Plasmodium falciparum; Plasmodium vivax; Single nucleotide polymorphisms and drug resistance; Sulphadoxine pyrimethamine

Indexed keywords

AMODIAQUINE; CHLOROQUINE; DIHYDROFOLATE REDUCTASE; DIHYDROPTEROATE SYNTHASE; MULTIDRUG RESISTANCE PROTEIN 1; PYRIMETHAMINE; SULFADOXINE; ANTIMALARIAL AGENT; PRIMAQUINE; PROTOZOAL PROTEIN;

ANTIMALARIAL DRUG RESISTANCE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEALTH CENTER; HONDURAS; HUMAN; HUMAN TISSUE; LABORATORY; MALARIA CONTROL; MALARIA FALCIPARUM; MEDICAL CARE; NUCLEOTIDE SEQUENCE; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM VIVAX MALARIA; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG EFFECT; DRUG RESISTANCE; GENETICS; ISOLATION AND PURIFICATION; PARASITOLOGY;

ANTIMALARIALS; CHLOROQUINE; DRUG RESISTANCE; HONDURAS; HUMANS; MALARIA, FALCIPARUM; MALARIA, VIVAX; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; POLYMORPHISM, SINGLE NUCLEOTIDE; PRIMAQUINE; PROTOZOAN PROTEINS;

EID: 83655203218     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-10-376     Document Type: Article

References (50)

1. National Malaria Programme, Malaria Guidelines in Honduras Tegucigalpa: Honduras Ministry of Health First 2010
2. National Malaria Programme, Malaria Situation in Honduras 2010 Tegucigalpa: Ministry of Health 2011
3. WHO, Global Report on antimalarial drug efficacy and drug resistance: 2000-2010. Geneva 2010
4. A molecular marker for chloroquine-resistant falciparum malaria. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, Coulibaly D, NEJM 2001 344 257 263 (Pubitemid 32108530)
5. Plasmodium falciparum genotypes associated with chloroquine and amodiaquine resistance in Guinea-Bissau. Ursing J, Kofoed PE, Rodrigues A, Rombo L, Gil JP, Am J Trop Med Hyg 2007 76 844 848 (Pubitemid 351627666)
6. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P, Malar J 2009 8 89
7. High-level chloroquine resistance in Sudanese isolates of Plasmodium falciparum is associated with mutations in the chloroquine resistance transporter gene pfcrt and the multidrug resistance Gene pfmdr1. Babiker HA, Pringle SJ, Abdel-Muhsin A, Mackinnon M, Hunt P, Walliker D, J Infect Dis 2001 183 1535 1538 (Pubitemid 32417707)
8. In vivo selection of Plasmodium falciparum pfmdr1 86N coding alleles by artemether-lumefantrine (Coartem). Sisowath C, Stromberg J, Martensson A, Msellem M, Obondo C, Bjorkman A, Gil JP, J Infect Dis 2005 191 1014 1017 (Pubitemid 40349821)
9. The role of pfmdr1 in Plasmodium falciparum tolerance to artemether-lumefantrine in Africa. Sisowath C, Ferreira PE, Bustamante LY, Dahlstrom S, Martensson A, Bjorkman A, Krishna S, Gil JP, Trop Med Int Health 2007 12 736 742 (Pubitemid 46872790)
10. In vitro activities of piperaquine, lumefantrine, and dihydroartemisinin in Kenyan Plasmodium falciparum isolates and polymorphisms in pfcrt and pfmdr1. Mwai L, Kiara SM, Abdirahman A, Pole L, Rippert A, Diriye A, Bull P, Marsh K, Borrmann S, Nzila A, Antimicrob Agents Chemother 2009 53 5069 5073
11. The pfmdr1 gene is associated with a multidrug-resistant phenotype in Plasmodium falciparum from the western border of Thailand. Price RN, Cassar C, Brockman A, Duraisingh M, van Vugt M, White NJ, Nosten F, Krishna S, Antimicrob Agents Chemother 1999 43 2943 2949
12. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ, Nosten F, Krishna S, Lancet 2004 364 438 447 (Pubitemid 39036891)
13. Molecular and pharmacological determinants of the therapeutic response to artemether-lumefantrine in multidrug-resistant Plasmodium falciparum malaria. Price RN, Uhlemann AC, van Vugt M, Brockman A, Hutagalung R, Nair S, Nash D, Singhasivanon P, Anderson TJ, Krishna S, White NJ, Nosten F, Clin Infect Dis 2006 42 1570 1577
14. Molecular epidemiology of malaria in Yaounde, Cameroon. VI. Sequence variations in the Plasmodium falciparum dihydrofolate reductase-thymidylate synthase gene and in vitro resistance to pyrimethamine and cycloguanil. Basco LK, Ringwald P, Am J Trop Med Hyg 2000 62 271 276 (Pubitemid 30257589)
15. Drug-resistant malaria-an insight. Hyde JE, FEBS J 2007 274 4688 4698 (Pubitemid 47354145)
16. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of Plasmodium falciparum malaria. Kublin JG, Dzinjalamala FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, J Infect Dis 2002 185 380 388 (Pubitemid 34107252)
17. Emergence of a dhfr mutation conferring high-level drug resistance in Plasmodium falciparum populations from southwest Uganda. Lynch C, Pearce R, Pota H, Cox J, Abeku TA, Rwakimari J, Naidoo I, Tibenderana J, Roper C, J Infect Dis 2008 197 1598 1604 (Pubitemid 351706491)
18. Gene amplification of the multidrug resistance 1 gene of Plasmodium vivax isolates from Thailand, Laos, and Myanmar. Imwong M, Pukrittayakamee S, Pongtavornpinyo W, Nakeesathit S, Nair S, Newton P, Nosten F, Anderson TJ, Dondorp A, Day NP, White NJ, Antimicrob Agents Chemother 2008 52 2657 2659 (Pubitemid 351915703)
19. Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms. Suwanarusk R, Russell B, Chavchich M, Chalfein F, Kenangalem E, Kosaisavee V, Prasetyorini B, Piera KA, Barends M, Brockman A, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN, PLoS One 2007 2 1089
20. Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax. Suwanarusk R, Chavchich M, Russell B, Jaidee A, Chalfein F, Barends M, Prasetyorini B, Kenangalem E, Piera KA, Lek-Uthai U, Anstey NM, Tjitra E, Nosten F, Cheng Q, Price RN, J Infect Dis 2008 198 1558 1564
21. Therapeutic efficacies of artesunate-sulfadoxine-pyrimethamine and chloroquine-sulfadoxine-pyrimethamine in vivax malaria pilot studies: relationship to Plasmodium vivax dhfr mutations. Tjitra E, Baker J, Suprianto S, Cheng Q, Anstey NM, Antimicrob Agents Chemother 2002 46 3947 3953 (Pubitemid 35403273)
22. Association of genetic mutations in Plasmodium vivax dhfr with resistance to sulfadoxine-pyrimethamine: geographical and clinical correlates. Imwong M, Pukrittakayamee S, Looareesuwan S, Pasvol G, Poirreiz J, White NJ, Snounou G, Antimicrob Agents Chemother 2001 45 3122 3127 (Pubitemid 32988838)
23. Dihydrofolate reductase mutations in Plasmodium vivax from Indonesia and therapeutic response to sulfadoxine plus pyrimethamine. Hastings MD, Porter KM, Maguire JD, Susanti I, Kania W, Bangs MJ, Sibley CH, Baird JK, J Infect Dis 2004 189 744 750 (Pubitemid 38270930)
24. Amino acid mutations in Plasmodium vivax DHFR and DHPS from several geographical regions and susceptibility to antifolate drugs. Auliff A, Wilson DW, Russell B, Gao Q, Chen N, Anh le N, Maguire J, Bell D, O'Neil MT, Cheng Q, Am J Trop Med Hyg 2006 75 617 621 (Pubitemid 46941264)
25. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Kongsaeree P, Khongsuk P, Leartsakulpanich U, Chitnumsub P, Tarnchompoo B, Walkinshaw MD, Yuthavong Y, Proc Natl Acad Sci USA 2005 102 13046 13051 (Pubitemid 41324976)
26. Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6). Dahlstrom S, Veiga MI, Ferreira P, Martensson A, Kaneko A, Andersson B, Bjorkman A, Gil JP, Infect Genet Evol 2008 8 340 345
27. Multiplex PCR-RFLP methods for pfcrt, pfmdr1 and pfdhfr mutations in Plasmodium falciparum. Veiga MI, Ferreira PE, Bjorkman A, Gil JP, Mol Cell Probes 2006 20 100 104 (Pubitemid 43343722)
28. Short report: polymorphisms in the pfcrt and pfmdr1 genes of Plasmodium falciparum and in vitro susceptibility to amodiaquine and desethylamodiaquine. Echeverry DF, Holmgren G, Murillo C, Higuita JC, Bjorkman A, Gil JP, Osorio L, Am J Trop Med Hyg 2007 77 1034 1038 (Pubitemid 351837788)
29. Multiple origins of resistance-conferring mutations in Plasmodium vivax dihydrofolate reductase. Hawkins VN, Auliff A, Prajapati SK, Rungsihirunrat K, Hapuarachchi HC, Maestre A, O'Neil MT, Cheng Q, Joshi H, Na-Bangchang K, Sibley CH, Malar J 2008 7 72
30. Genetic polymorphism in pvmdr1 and pvcrt-o genes in relation to in vitro drug susceptibility of Plasmodium vivax isolates from malaria-endemic countries. Lu F, Lim CS, Nam DH, Kim K, Lin K, Kim TS, Lee HW, Chen JH, Wang Y, Sattabongkot J, Han ET, Acta Trop 2011 117 69 75
31. Assessment of chloroquine sensitivity of Plasmodium falciparum in Choluteca, Honduras. Nguyen-Dinh P, Hobbs JH, Campbell CC, Bull World Health Organ 1981 59 641 646 (Pubitemid 12013487)
32. Evaluate the clinical and parasitological efficacy of chloroquine in the treatment of malaria in children. Hospital Escuela 1998-2000, Tegucigalpa, Honduras. Mejía-Díaz JR, Alger J, Valenzuela-Castillo R, Jeremías-Soto R, Revista Medica de los Postgrados de Medicina 2000 5 97 104
33. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC, Mol Biochem Parasit 2000 108 13 23 (Pubitemid 30236312)
34. Origins and spread of pfdhfr mutant alleles in Plasmodium falciparum. Mita T, Acta Trop 2010 114 166 170
35. Spread and evolution of Plasmodium falciparum drug resistance. Mita T, Tanabe K, Kita K, Parasitol Int 2009 58 201 209
36. Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum. Barnes KI, White NJ, Acta Trop 2005 94 230 240 (Pubitemid 40720329)
37. Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations. Lawpoolsri S, Klein EY, Singhasivanon P, Yimsamran S, Thanyavanich N, Maneeboonyang W, Hungerford LL, Maguire JH, Smith DL, Malar J 2009 8 159
38. Resistance to therapies for infection by Plasmodium vivax. Baird JK, Clin Microbiol Rev 2009 22 508 534
39. Recurrent parasitemias and population dynamics of Plasmodium vivax polymorphisms in rural Amazonia. Orjuela-Sanchez P, da Silva NS, da Silva-Nunes M, Ferreira MU, Am J Trop Med Hyg 2009 81 961 968
40. Plasmodium vivax dhfr and dhps mutations in isolates from Madagascar and therapeutic response to sulphadoxine-pyrimethamine. Barnadas C, Tichit M, Bouchier C, Ratsimbasoa A, Randrianasolo L, Raherinjafy R, Jahevitra M, Picot S, Menard D, Malar J 2008 7 35
41. Different allele prevalence in the dihydrofolate reductase and dihydropteroate synthase genes in Plasmodium vivax populations from China. Miao M, Yang Z, Cui L, Ahlum J, Huang Y, Am J Trop Med Hyg 2010 83 1206 1211
42. Characterisation of pvmdr1 and pvdhfr genes associated with chemoresistance in Brazilian Plasmodium vivax isolates. Gama BE, Oliveira NK, Souza JM, Daniel-Ribeiro CT, Ferreira-da-Cruz Mde F, Mem Inst Oswaldo Cruz 2009 104 1009 1011
43. Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region. Orjuela-Sanchez P, de Santana Filho FS, Machado-Lima A, Chehuan YF, Costa MR, Alecrim MG, del Portillo HA, Antimicrob Agents Chemother 2009 53 3561 3564
44. High prevalence and fixation of Plasmodium vivax dhfr/dhps mutations related to sulfadoxine/pyrimethamine resistance in French Guiana. Barnadas C, Musset L, Legrand E, Tichit M, Briolant S, Fusai T, Rogier C, Bouchier C, Picot S, Menard D, Am J Trop Med Hyg 2009 81 19 22
45. Novel point mutations in the dihydrofolate reductase gene of Plasmodium vivax: evidence for sequential selection by drug pressure. Imwong M, Pukrittayakamee S, Renia L, Letourneur F, Charlieu JP, Leartsakulpanich U, Looareesuwan S, White NJ, Snounou G, Antimicrob Agents Chemother 2003 47 1514 1521 (Pubitemid 36548531)
46. Plasmodium vivax dihydrofolate reductase point mutations from the Indian subcontinent. Kaur S, Prajapati SK, Kalyanaraman K, Mohmmed A, Joshi H, Chauhan VS, Acta Trop 2006 97 174 180 (Pubitemid 43087751)
47. Plasmodium vivax: prevalence of mutations associated with sulfadoxine-pyrimethamine resistance in Plasmodium vivax clinical isolates from Pakistan. Zakeri S, Afsharpad M, Ghasemi F, Raeisi A, Kakar Q, Atta H, Djadid ND, Exp Parasitol 2011 127 167 172
48. Molecular characterization of antifolates resistance-associated genes, (dhfr and dhps) in Plasmodium vivax isolates from the Middle East. Zakeri S, Motmaen SR, Afsharpad M, Djadid ND, Malar J 2009 8 20
49. Antifolates can have a role in the treatment of Plasmodium vivax. Hawkins VN, Joshi H, Rungsihirunrat K, Na-Bangchang K, Sibley CH, Trends Parasitol 2007 23 213 222 (Pubitemid 46621225)
50. Strengthening Pharmaceutical Program, Situation of management of medicines supply for treatment of malaria in Central America countries. Presented to United States Agency for International Development by the SPS Program Health MSf ed. Arlington, VA 2008